Divalproex Sodium in Substance Abusers With Mood Disorder
The DOI matches its Crossref record.
Abstract
BACKGROUND: Substance abuse is a common comorbid illness in patients with mood disorders. Little has been written about the pharmacologic treatment of patients with affective lability and co-occurring substance abuse, however. The following report will describe clinical experience using divalproex sodium in substance-abusing patients with mood disorder. METHOD: Twenty patients admitted to an intermediate-care inpatient substance abuse program were diagnosed with comorbid mood disorder (according to DSM-IV criteria) and treated with divalproex sodium in an open-label, naturalistic trial with no blind. All patients were followed clinically and were assessed using the Clinical Global Impressions scale (CGI) and laboratory studies. RESULTS: Seven patients referred while on divalproex treatment continued to exhibit improved mood. Eleven others had at least 1 week of follow-up, and 10 of these also showed improvement. In 13 cases, divalproex was used safely with other psychiatric medications. Two patients complained of slight tremor, 1 of whom was also taking fluoxetine. Fifteen of 17 patients in whom biochemistry and hematology laboratory studies were completed had unremarkable results; 2 other patients had pretreatment abnormalities, which worsened over the course of treatment. Mean plasma valproate level was 58.53 microg/mL. Mean length of follow-up was 38 days. Mean period of abstinence prior to starting medication was 48 days. Some patients reported decreased cravings, and, by self-report, all patients remained abstinent. CONCLUSION: This report suggests that divalproex sodium is efficacious and safe, both alone and in combination with other psychiatric medications, in treating substance-abusing patients with mood disorder.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lithium or divalproex, either alone or in combination, were proven useful in small studies addressing cocaine use disorder682, 685, 686, 687, 707, 708 (level 4).”
In the citing paper
“There is only level 3 evidence for lamotrigine,684 and divalproex monotherapy or add‐on.685, 686, 687”
Citations
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Psychiatric and Medical Comorbidities of Bipolar Disorder
Krishnan, K. R. R. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000151489.36347.18 · Cited by 502
“Complications of substance abuse in bipolar disorder include higher rates of mixed and rapid cycling mania (21), prolonged recovery time (21), higher prevalence of medical disorders including liver disease (18), more suicide attempts (22), and suicide (20,23,24).”
BackgroundMood Disorders and Substance Use Disorder: A Complex Comorbidity
Quello, S., Brady, K., & Sonne, S. (2005) · Science & Practice Perspectives · doi:10.1151/spp053113 · Cited by 320
“Several small pilot studies have shown that patients with bipolar-SUD comorbidity benefit from valproate and tolerate it well (Albanese, Clodfelter, and Khantzian, 2000; Brady et al., 1995; Hertzman, 2000).”
BackgroundLevin, F. R., McDowell, D., Evans, S. M., Nunes, E., Akerele, E., Donovan, S., & Vosburg, S. K. (2004) · The American Journal on Addictions · doi:10.1080/10550490490265280 · Cited by 113
Management of comorbid bipolar disorder and substance use disorders
Salloum, I. M., & Brown, E. S. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2017.1292279 · Cited by 91
“Also, open-label pilot studies have found sodium valproate (63 – 65) useful for decreasing alcohol abuse, and lamotrigine (66) was reported to be helpful in the treatment of cocaine abuse in bipolar disorder.”
Metadata
- Authors
- Albanese, M. J., Clodfelter, R. C., & Khantzian, E. J.
- Affiliations
- Commonwealth of Massachusetts (US)
- ORCID
- Khantzian, Edward J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2000-12-15
- Volume
- 61
- Issue
- 12
- Pages
- 916-921
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2028878833
- Cited by
- 40
- References
- 0
- Citations by year
- 2026: 1 · 2023: 1 · 2021: 2 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 1 · 2012: 1
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- divalproex sodium, valproic acid, substance abuse, mood disorders, emotional lability, comorbidities, bipolar disorder, drug safety, combination pharmacotherapy, alcohol craving, abstinence
- MeSH terms
- Adult, Anticonvulsants, Bipolar Disorder, Depressive Disorder, Drug Therapy, Combination, Follow-Up Studies, Hospitalization, Humans, Male, Middle Aged, Psychotropic Drugs, Valproic Acid, Comorbidity, Substance Abuse Treatment Centers, Panic Disorder, Behavior, Addictive, Treatment Outcome, Mood Disorders, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Divalproex Sodium in Substance Abusers With Mood Disorder. https://app.cochat.ai/papers/10.4088/jcp.v61n1205
- The paper
- Albanese, M. J., Clodfelter, R. C., & Khantzian, E. J. (2000). Divalproex Sodium in Substance Abusers With Mood Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v61n1205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.